Release date: 2017-01-11 A study from The Cancer Genome Atlas Research Network (TCGA) was published in the recent issue of Nature (click on the bottom left corner to read the original text), which includes two aspects. First, the upper esophageal cancer is more similar to head and neck cancer, while the lower esophageal tumor is almost the same as a subtype of gastric cancer. Second, cancer clinical trials should classify patients based on molecular subtypes. Typically, the lower esophageal cancer is classified as gastric cancer and is distinguished from the upper esophageal cancer. Adam Bass, one of the heads of TCGA esophageal cancer research, is also a clinical scientist at the Dana-Farber Cancer Institute in the United States. He said: "This study has deepened our understanding of esophageal cancer genomics. We hope this research will solve some of Long-standing uncertainties in the field of esophageal cancer, and as a reference manual for researchers and drug developers, seek more effective clinical trials and new treatments." For decades, doctors have known that esophageal cancer can be classified into two categories when viewed under a microscope: esophageal adenocarcinoma (similar to gastric or rectal cancer) and squamous cell carcinoma (similar to lung cancer, skin cancer, and head and neck cancer). . What has not yet been determined is the extent to which molecular features of esophageal adenomas and squamous cell carcinomas differ, as well as the relationship between esophageal adenocarcinoma and gastric adenocarcinoma. Dr. Peter W. Laird, a principal investigator of the International TCGA Research Network and a professor at the Wenlow Institute in the United States, said: "We already know that there are significant differences in molecular subtypes between these clinical subtypes. These findings suggest that The difference between the origin of the tumor and the esophagus is not as great as the difference in the molecular characteristics of the tumor." Only 1% of newly diagnosed cancers in the United States are esophageal cancers. However, 80% of people will die after diagnosis, and current treatments usually don't help. In addition, cases of esophageal adenocarcinoma have increased dramatically over the past 40 years and have grown sevenfold since the 1970s. In this field, there has been a huge uncertainty about the relationship between esophageal adenocarcinoma and gastric adenocarcinoma. The new report opposes continuing to debate the line between esophageal cancer and gastric adenocarcinoma, but instead treats gastroesophageal adenocarcinoma as a more single entity, similar to rectal cancer. The key is that this study reveals that the esophageal adenocarcinoma has striking molecular similarity to a type of gastric cancer (chromosome-stable tumor), which is characterized by significant chromosome structural aberrations. Oncologists say that this subtle view of the disease, including the detailed molecular classification of esophageal adenocarcinoma, is likely to change research and treatment. Yelena Y. Janjigian, a gastrointestinal oncologist at the Sloan Kettering Cancer Center, said: "It is clear from the TCGA data that esophageal squamous cell carcinoma and esophageal adenocarcinoma are completely different diseases and should not be the same. Treatment trials. For esophageal adenocarcinoma, it seems that the combination of pathways and therapeutic strategies can be effective. The therapeutic implications of these changes will be explored in subsequent studies." Members of the TCGA Research Network team say these studies represent the work of a dedicated collaborator who works hard to find new ways to fight cancer. Dr. Ilya Shmulevich, a professor at the Institute of Systems Biology, said: "TCGA's research goes beyond the research of any single institution or individual. These great undertakings can only be achieved through hundreds of experts and scientific cooperation contributions from around the world. These projects have dedicated their youth and hope to find new ways to treat diseases for humans." Source: China Biotechnology Network The Anti Rabies Vaccine For Human vaccine can prevent rabies. Rabies is a serious illness caused by a virus. The rabies virus is spread to humans through the bite or scratch of an infected animal. Dogs, bats, skunks, coyotes, raccoons, and foxes are examples of animals that can carry rabies. The rabies vaccine can protect you from infection if you are at high risk of exposure. The vaccine can also prevent infection after you are bitten by an infected animal. Anti Rabies Vaccine For Human,Rabies Vaccine Dose,Human Freeze Anti Rabies Vaccine,Rabies Vaccine Vero Cell For Human Changchun Zhuoyi Biological Co., Ltd , https://www.zhuoyibiological.com
Research reveals that esophageal cancer is two different types of diseases